Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Hutchmed (China) Limited (HCM) ORD USD0.10

Sell:536.00p Buy:540.00p 0 Change: 28.00p (4.96%)
FTSE AIM 100:0.32%
Market closed Prices as at close on 27 July 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Change: 28.00p (4.96%)
Market closed Prices as at close on 27 July 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Change: 28.00p (4.96%)
Market closed Prices as at close on 27 July 2021 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.

Contact details

22Nd Floor Hutchison House
10 Harcourt Road

Hong Kong
+852 (0) 21281188

Important dates

Future events
There are no future events available.
Past events
Interim results 28 July 2021 28/07/21
AGM 28 April 2021 28/04/21
Annual report 26 March 2021 26/03/21
Final results 04 March 2021 04/03/21
Interim results 30 July 2020 30/07/20

General stock information

Market cap:
£4.64 billion
Shares in issue:
864.12 million
Pharmaceuticals & Biotechnology
London Stock Exchange
Sterling pence

Key personnel

  • Simon To
    Executive Chairman of the Board
  • Christian Hogg
    Chief Executive Officer, Executive Director
  • Chig Fung Cheng
    Chief Financial Officer, Executive Director
  • Mark Lee
    Senior Vice President - Corporate Finance & Development
  • May Wang
    Senior Vice President - business development & strategic alliances
  • Zhenping Wu
    Senior Vice President - Pharmaceutical Sciences
  • Weiguo Su
    Chief Scientific Officer, Executive Director
  • Edith Shih
    Company Secretary, Non-Executive Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.